656798-50-4

Upstream product

• 20691-72-9 4-iodo-2-nitroaniline 
• 875-51-4 4-Bromo-2-nitroaniline 
• 518982-26-8 2-nitro-4-(trimethylsilanylethynyl)phenylamine 

Downstream Products

• 656798-49-1 2-nitro-4-pentafluorophenylethynylaniline 
• 947311-93-5 4-(1H-indazol-6-ylethynyl)-2-nitrophenylamine 
• 58297-31-7 4-ethynylbenzene-1,2-diamine 
• 1333406-69-1 C₁₇H₁₇N₅O₃ 
• 1333406-64-6 4-(1-phenethyl-1,2,3-triazol-4-yl)-2-nitroaniline 
• 1333406-52-2 5-(1-(3-methoxyphenethyl)-1H-1,2,3-triazol-4-yl)-1H-benzo[d]imidazole 
• 1333406-51-1 5-(1-(4-methoxyphenethyl)-1H-1,2,3-triazol-4-yl)-1H-benzo[d]imidazole 
• 1333406-48-6 C₁₇H₁₅N₅ 
• 1333406-67-9 C₁₈H₁₉N₅O₄ 
• 1333406-68-0 4-(1-(4-methoxyphenylethyl)-1,2,3-triazol-4-yl)-2-nitroaniline 

Relevant academic research and scientific papers

BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING SAME

Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1 ), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.

PHOSPHORESCENT TRANSITION METAL COMPLEX, ITS PREPARATION AND USE

A phosphorescent transition metal complex especially suitable as sensor for hydrogen peroxide in cells, in particular in mitochondria in live cells, includes a metallic central atom, which is a transition metal, a first ligand with at least one pyridine r

New class of bioluminogenic probe based on bioluminescent enzyme-induced electron transfer: BioLeT

Bioluminescence imaging (BLI) has advantages for investigating biological phenomena in deep tissues of living animals, but few design strategies are available for functional bioluminescent substrates. We propose a new design strategy (designated as bioluminescent enzyme-induced electron transfer: BioLeT) for luciferin-based bioluminescence probes. Luminescence measurements of a series of aminoluciferin derivatives confirmed that bioluminescence can be controlled by means of BioLeT. Based on this concept, we developed bioluminescence probes for nitric oxide that enabled quantitative and sensitive detection even in vivo. Our design strategy should be applicable to develop a wide range of practically useful bioluminogenic probes.

Effect of head group size on the photoswitching applications of azobenzene Disperse Red 1 analogues

We investigate the effect of the increased molecular bulk in the 'head' group for a class of newly synthesized azobenzene chromophores with a clickable ethynyl group para and a nitro group ortho to the azo bond on the distal benzene ring. This 'variable-head' functionalization provides a family of dyes with photophysical characteristics very similar to those of Disperse Red 1, one of the most commonly used azo dyes in materials science. Phenyl, naphthyl, and anthracyl derivatives were synthesized as small molecules, monomers, homopolymers, and copolymers in a rapid and facile manner using click chemistry, confirming the versatility of this parent chromophore. Photochemical and spectral studies indicate that this strategy is suitable to build a 'bulkiness series' of stimuli-responsive materials, as the various material derivatives retain the absorption and kinetic characteristics of the parent chromophore necessary for all optical patterning applications that DR1 dyes have been optimized for. In thin films, larger head group size was found to increase the stability of light-induced birefringence in copolymers. The homopolymers formed stable surface-relief gratings upon interference irradiation, whose grating depths correlate with head group size, demonstrating that this new class of polymers can also undergo tailored macroscopic photoinduced motions, which could have applications in all optical nano-patterning. the Partner Organisations 2014.

PROTEIN KINASE INHIBITORS

A compound of formula (I), wherein R1 to R5, A, B, Z, Z1 and Z2 are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.

Bridging ligand length controls at selectivity and enantioselectivity of binuclear ruthenium threading intercalators

The slow dissociation of DNA threading intercalators makes them interesting as model compounds in the search for new DNA targeting drugs, as there appears to be a correlation between slow dissociation and biological activity. Thus, it would be of great value to understand the mechanisms controlling threading intercalation, and for this purpose we have investigated how the length of the bridging ligand of binuclear ruthenium threading intercalators affects their DNA binding properties. We have synthesised a new binuclear ruthenium threading intercalator with slower dissociation kinetics from ct-DNA than has ever been observed for any ruthenium complex with any type of DNA, a property that we attribute to the increased distance between the ruthenium centres of the new complex. By comparison with previously studied ruthenium complexes, we further conclude that elongation of the bridging ligand reduces the sensitivity of the threading interaction to DNA flexibility, resulting in a decreased AT selectivity for the new complex. We also find that the length of the bridging ligand affects the enantioselectivity with increasing preference for the ΔΔ enantiomer as the bridging ligand becomes longer. Copyright

Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold

Glutaminyl cyclase (hQC) has emerged as a new potential target for the treatment of Alzheimer's disease (AD). The inhibition of hQC prevents of the formation of the Aβ3(pE)-40,42 species which were shown to be of elevated neurotoxicity and are likely to act as a seeding core, leading to an accelerated formation of Aβ-oligomers and fibrils. This work presents a new class of inhibitors of hQC, resulting from a pharmacophore-based screen. Hit molecules were identified, containing benzimidazole as the metal binding group connected to 1,3,4-oxadiazole as the central scaffold. The subsequent optimization resulted in benzimidazolyl-1,3,4-thiadiazoles and -1,2,3-triazoles with an inhibitory potency in the nanomolar range. Further investigation into the potential binding mode of the new compound classes combined molecular docking and site directed mutagenesis studies.

NOVEL INHIBITORS

The invention relates to novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS AURORA KINASE INHIBITORS

The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.